This article needs additional citations for verification . (September 2019) (Learn how and when to remove this template message)
|Edited by||Eric Rubin|
|The New England Journal of Medicine and Surgery, The New England Medical Review and Journal, The Boston Medical and Surgical Journal|
Massachusetts Medical Society (United States)
|Delayed (6 months)|
|Bluebook||New Eng. J. Med.|
|ISO 4||N. Engl. J. Med.|
|ISSN|| 0028-4793 (print)|
The New England Journal of Medicine (NEJM) is a weekly medical journal published by the Massachusetts Medical Society. It is among the most prestigious peer-reviewed medical journalsas well as the oldest continuously published one.
In September 1811, John Collins Warren, a Boston physician, [ citation needed ]along with James Jackson, submitted a formal prospectus to establish the New England Journal of Medicine and Surgery and Collateral Branches of Science as a medical and philosophical journal. Subsequently, the first issue of the New England Journal of Medicine and Surgery and the Collateral Branches of Medical Science was published in January 1812. The journal was published quarterly.
On April 29, 1823, another publication, the Boston Medical Intelligencer, appeared under the stewardship of Jerome V. C. Smith.
The Intelligencer ran into financial troubles in the spring of 1827, and the editors of the New England Journal of Medicine and Surgery and the Collateral Branches of Medical Science purchased it in February 1828 merging the two publications to form the Boston Medical and Surgical Journal, [ citation needed ]published weekly.
In 1921, the Massachusetts Medical Society purchased the Journal for US$1 equivalent to $14in 2019) and, in 1928, renamed it to The New England Journal of Medicine.[ citation needed ](
The journal's logo depicts the Rod of Asclepius crossed over a quill pen. The dates on the logo represent the founding of the components of The New England Journal of Medicine: 1812 for the New England Journal of Medicine and Surgery and Collateral Branches of Medical Science, 1823 for the Boston Medical Intelligencer, 1828 for the Boston Medical and Surgical Journal, and 1928 for the New England Journal of Medicine.[ citation needed ]
Notable articles from the course of The New England Journal of Medicine's history include:
On April 25, 1996, the NEJM announced a new web site, which published each week the abstracts for research articles and the full text of editorials, cases, and letters to the editor. After print publishing for 184 years this was the NEJM's first use of the Internet for electronic publication.
The site was launched several months earlier in 1996, but the editors wanted proof that weekly electronic publication would work. Only then was an announcement approved for publication on the editorial page. Two years later, online publication extended to include the full text of all articles. [ not specific enough to verify ]
Since its launch, NEJM has added to its site:[ citation needed ]
The George Polk Awards site noted that its 1977 award to The New England Journal of Medicine: "...provided the first significant mainstream visibility for a publication that would achieve enormous attention and prestige in the ensuing decades."
The journal usually has the highest impact factor of the journals of internal medicine. According to the Journal Citation Reports, NEJM had a 2017 impact factor of 79.258,ranking it first of 153 journals in the category "General & Internal Medicine". It was the only journal in the category with an impact factor of more than 70. By comparison, the second and third ranked journals in the category ( The Lancet and JAMA) had impact factors of 53.254 and 47.661 respectively.
The New England Journal of Medicine requires that articles it publishes have not been published or released elsewhere. Referred to as the Ingelfinger rule, this policy protects the originality of content.[ citation needed ]
The rule was first described in a 1969 editorial by Franz Ingelfinger, the editor-in-chief at that time. A number of medical journals have similar rules in place.[ citation needed ]
In the early 2000s, The New England Journal of Medicine was involved in a controversy around problems with research on the drug Vioxx. A study was published in the journal in November 2000 which noted an increase in myocardial infarction amongst those taking Vioxx.According to Richard Smith, the former editor of the British Medical Journal , concerns about the correctness of that study were raised with the journal's editor, Jeff Drazen, as early as August 2001. That year, both the US Food and Drug Administration and the Journal of the American Medical Association also cast doubt on the validity of the data interpretation that had been published in the NEJM. Merck withdrew the drug from market in September 2004. In December 2005, NEJM published an expression of concern about the original study following discovery that the authors knew more about certain adverse events than they disclosed at the time of publication. From the Expression of Concern: "Until the end of November 2005, we believed that these were late events that were not known to the authors in time to be included in the article published in the Journal on November 23, 2000. It now appears, however, from a memorandum dated July 5, 2000, that was obtained by subpoena in the Vioxx litigation and made available to the Journal, that at least two of the authors knew about the three additional myocardial infarctions at least two weeks before the authors submitted the first of two revisions and 4 1/2 months before publication of the article." During the five-year period between publication and Expression of Concern, it has been estimated that Merck paid NEJM as much as US$836,000 for article reprints that Merck used for promotional purposes. The journal was publicly rebuked for its response to the research issues in editorials appearing in publications including the British Medical Journal and the Journal of the Royal Society of Medicine .
NEJM provides delayed free online access to its research articles (it does so six months after publication, and maintains that access dating back to 1990).This delay does not apply to readers from the least developed countries, for whom the content is available at no charge for personal use.
NEJM also has two podcast features, one with interviews of doctors and researchers that are publishing in the journal, and another summarizing the content of each issue. Other offerings include Continuing Medical Education, Videos in Clinical Medicine (showing videos of medical procedures), and the weekly Image Challenge.
The BMJ is a weekly peer-reviewed medical trade journal, published by the trade union the British Medical Association (BMA). The BMJ has editorial freedom from the BMA. It is one of the world's oldest general medical journals. Originally called the British Medical Journal, the title was officially shortened to BMJ in 1988, and then changed to The BMJ in 2014. The journal is published by BMJ Publishing Group Ltd, a subsidiary of the British Medical Association (BMA). The editor-in-chief of The BMJ is Fiona Godlee, who was appointed in February 2005.
Rofecoxib was a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea. Rofecoxib was approved in the US by the US Food and Drug Administration (FDA) in May 1999, and was marketed under the brand names Vioxx, Ceoxx, and Ceeoxx. Rofecoxib was available by prescription in both tablet-form and as an oral suspension.
Science by press conference is the practice by which scientists put an unusual focus on publicizing results of research in the media. The term is usually used disparagingly. It is intended to associate the target with people promoting scientific "findings" of questionable scientific merit who turn to the media for attention when they are unlikely to win the approval of the professional scientific community.
Yellapragada Subbarow was a pioneering Indian biochemist who discovered the function of adenosine triphosphate (ATP) as an energy source in the cell, developed methotrexate for the treatment of cancer and led the department at Lederle laboratories in which Benjamin Minge Duggar discovered chlortetracycline (Aureomycin) in 1945.
Actinomycosis is a rare infectious bacterial disease caused by Actinomyces species. About 70% of infections are due to either Actinomyces israelii or A. gerencseriae. Infection can also be caused by other Actinomyces species, as well as Propionibacterium propionicus, which presents similar symptoms. The condition is likely to be polymicrobial aerobic anaerobic infection.
The era of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards and folic acid antagonist drugs. The targeted therapy revolution has arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers still apply.
Sidney Farber was an American pediatric pathologist. He is regarded as the father of modern chemotherapy for his work using folic acid antagonists to combat leukemia, which led to the development of other chemotherapeutic agents against other malignancies. Farber was also active in cancer research advocacy and fundraising, most notably through his establishment of the Jimmy Fund, a foundation dedicated to pediatric research in childhood cancers. The Dana–Farber Cancer Institute is named after him.
John Roland Darsee is an American physician and former medical researcher. After compiling an impressive list of publications in reputable scientific journals, he was found to have fabricated data for his publications.
In journalism and public relations, a news embargo or press embargo is a request or requirement by a source that the information or news provided by that source not be published until a certain date or certain conditions have been met. They are often used by businesses making a product announcement, by medical journals, and by government officials announcing policy initiatives; the media is given advance knowledge of details being held secret so that reports can be prepared to coincide with the announcement date and yet still meet press time.
Anterior temporal lobectomy is the complete removal of the anterior portion of the temporal lobe of the brain. It is a treatment option in temporal lobe epilepsy for those in whom anticonvulsant medications do not control epileptic seizures.
Arnold Seymour Relman — known as Bud Relman to intimates — was an American internist and professor of medicine and social medicine. He was editor of The New England Journal of Medicine (NEJM) from 1977 to 1991, where he instituted two important policies: one asking the popular press not to report on articles before publication and another requiring authors to disclose conflicts of interest. He wrote extensively on medical publishing and reform of the U.S. health care system, advocating non-profit delivery of single-payer health care. Relman ended his career as professor emeritus at Harvard Medical School in Boston, Massachusetts.
Franz Joseph Ingelfinger was a German-American physician, researcher and journal editor. He served as Chief of Gastroenterology at Evans Memorial Department of Clinical Research, part of Boston University School of Medicine. He also served as Editor of the New England Journal of Medicine (NEJM) from 1967 to 1976. His work was influential in the field of science journalism.
Donald S. Kornfeld is an American psychiatrist best known for his work on psychiatric issues associated with medical practice. This subspecialty is known as Consultation-Liaison Psychiatry or Psychosomatic Medicine.
In scientific publishing, the 1969 Ingelfinger rule originally stipulated that The New England Journal of Medicine (NEJM) would not publish findings that had been published elsewhere, in other media or in other journals. The rule was subsequently adopted by several other scientific journals, and has shaped scientific publishing ever since. Historically it has also helped to ensure that the journal's content is fresh and does not duplicate content previously reported elsewhere, and seeks to protect the scientific embargo system.
Timothy E. Quill is an American physician specialising in palliative care at the University of Rochester Medical Center in Rochester, New York. He is also a board member of the Death with Dignity National Center in Portland, Oregon. Quill was the lead plaintiff in a case that eventually reached the Supreme Court of the United States in 1997, Vacco v. Quill, in which the Court decided that a state law against physician-assisted suicide was constitutional.
Anthony L. Komaroff is an American physician, clinical investigator, editor, and publisher. He serves as the Distinguished Simcox-Clifford-Higby Professor of Medicine at Harvard Medical School and Senior Physician at Brigham and Women's Hospital in Boston.
MitraClip is a medical device used to treat mitral valve regurgitation for individuals who should not have open-heart surgery. It is implanted via a tri-axial transcatheter technique and involves suturing together the anterior and posterior mitral valve leaflets.
Eugene Wesley Ely Jr. is an American physician and professor of medicine as the Grant W. Liddle Endowed Chair at Vanderbilt University School of Medicine. He is conducting research as a geriatric intensivist in the Division of Pulmonary and Critical Care Medicine and the Center for Health Services Research at Vanderbilt University Medical Center. He is also the associate director of research at the Tennessee Valley Geriatric Research Education and Clinical Center (GRECC), part of the U.S. Department of Veterans Affairs.
Syrosingopine is a drug, derived from reserpine. It is used to treat hypertension.
John Ware was an American physician and fellow of the American Academy of Arts and Sciences.